GlassScriptPhysician profile
Paul R Porter
NPI 1134154461
$5,410.61
in general payments reported to CMS, 2019-2025
33 companies · $413 in 2025
The $413 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,114 · 2020: $1,004 · 2021: $899 · 2022: $794 · 2023: $711 · 2024: $476 · 2025: $413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,599.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $809.04 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $524.79 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $435.10 | 2019-2025 | Airsupra, Breztri |
| Amgen INC. | $393.20 | 2019-2024 | Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $342.91 | 2019-2025 | Leqvio |
| Merck Sharp & Dohme LLC | $339.82 | 2019-2023 | Verquvo, Belsomra, Lagevrio |
| Janssen Pharmaceuticals, INC | $297.74 | 2019-2023 | Xarelto |
| Glaxosmithkline, LLC. | $289.35 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $244.00 | 2020-2024 | Jardiance |
| Astellas Pharma US INC | $237.52 | 2020-2023 | Veozah |
| Lilly USA, LLC | $188.47 | 2020-2025 | Zepbound, Mounjaro |
| Pfizer INC. | $174.91 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $173.87 | 2023-2025 | |
| Abbvie INC. | $126.92 | 2022 | |
| Valeritas, INC. | $103.36 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $103.13 | 2021-2024 | Freestyle Libre 2 |
| Insulet Corporation | $94.18 | 2021-2023 | Omnipod |
| Exact Sciences Corporation | $72.38 | 2023-2025 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $67.92 | 2021-2022 | |
| Zealand Pharma US, INC. | $50.78 | 2022 | |
| Sumitomo Pharma America, INC. | $46.00 | 2023-2025 | Gemtesa |
| Regeneron Healthcare Solutions, INC. | $44.98 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $39.94 | 2023 | Inpefa |
| Kowa Pharmaceuticals America, INC. | $33.94 | 2020-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $27.04 | 2025 | Caplyta |
| Ascensia Diabetes Care US INC. | $23.94 | 2023 | |
| Medicure Pharma INC. | $23.74 | 2023 | Zypitamag |
| Esperion Therapeutics, INC. | $20.44 | 2021 | |
| Corcept Therapeutics | $19.95 | 2025 | Korlym |
| Alnylam Pharmaceuticals INC. | $18.95 | 2024 | Givlaari |
| Mannkind Corporation | $15.45 | 2023 | Afrezza |
| Boston Scientific Corporation | $15.21 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.64 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Porter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.